Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS -0.67%·Rev n/aQ1 23EPS +14.53%·Rev n/aQ4 22EPS +100.00%*·Rev n/aQ3 22EPS +12.87%·Rev n/a⚠ consensus missing

AGIOS PHARMACEUTICALS, INC. AGIO

Christopher Taylor — Investor Relations

Brian Goff — Chief Executive Officer

Sarah Gheuens — Chief Medical Officer

Tsveta Milanova — Chief Commercial Officer

Cecilia Jones — Chief Financial Officer

−0.2%1d on move date+0.1% vs SPY3d−1.7%5d+0.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AGIO calls or request research access.

More AGIO calls Browse calls Request research access